-
Electronic (PDF)
-
Site License
-
Enterprisewide
Reata Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 61
Reata Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Reata Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Reata Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Reata Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Reata Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Reata Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Reata Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Reata Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Reata Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Reata Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Reata Pharmaceuticals, Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
Reata Pharmaceuticals, Inc. Snapshot
Reata Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Reata Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Reata Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Reata Pharmaceuticals, Inc. – Pipeline Products Glance
Reata Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Reata Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Reata Pharmaceuticals, Inc. – Drug Profiles
Bardoxolone Methyl
Product Description
Mechanism of Action
R&D Progress
Berubicin
Product Description
Mechanism of Action
R&D Progress
Bardoxolone Methyl
Product Description
Mechanism of Action
R&D Progress
Berubicin
Product Description
Mechanism of Action
R&D Progress
AIMs for CNS Diseases
Product Description
Mechanism of Action
R&D Progress
AIMs for respiratory diseases
Product Description
Mechanism of Action
R&D Progress
Peloruside A
Product Description
Mechanism of Action
R&D Progress
RTA 203
Product Description
Mechanism of Action
R&D Progress
RTA 403
Product Description
Mechanism of Action
R&D Progress
RTA 502
Product Description
Mechanism of Action
R&D Progress
RTA 801
Product Description
Mechanism of Action
R&D Progress
Reata Pharmaceuticals, Inc. – Pipeline Analysis
Reata Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Reata Pharmaceuticals, Inc. Pipeline Products By Target
Reata Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Reata Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Reata Pharmaceuticals, Inc. – Recent Pipeline Updates
Reata Pharmaceuticals, Inc. - Dormant Projects
Reata Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 22, 2010: Reata And Abbott Announce Positive Phase IIb Chronic Kidney Disease Study Results For Bardoxolone Methyl
Nov 11, 2010: Reata Pharmaceuticals To Present Data From Pivotal Phase IIb Trial In Type 2 Diabetics With Chronic Kidney Disease
Nov 11, 2010: Reata Pharmaceuticals To Present Data From Pivotal Phase IIb Trial In Type 2 Diabetics With Chronic Kidney Disease
Jun 06, 2009: Reata Presents Promising Data On Bardoxolone At American Diabetes Association Annual Scientific Meeting
Feb 18, 2009: Reata's Antioxidant Inflammation Modulator Shows Promise For COPD In Study Published In Proceedings Of The National Academy Of Sciences
Jun 01, 2008: First-In-Man Study of RTA 402 Yields Promising Results in Patients with Advanced Cancers
Apr 09, 2008: Updated Data On Reata's Two Clinical Candidates, Berubicin Hydrochloride And RTA 402, Presented At 2008 Annual Meeting Of The American Association Of Cancer Research
Oct 24, 2007: Results Of Reata Pharmaceuticals' RTA 402 Phase I Cancer Trial Presented At AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference
Oct 18, 2007: Industry Leaders Select Reata Pharmaceuticals' RTA 402 As Top 10 Most Promising New Cancer Drugs
Nov 15, 2006: Reata Pharmaceuticals' RTA 402 Shown to Prevent Development of Lung Cancer
Financial Deals Landscape
Reata Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Reata Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Reata Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Reata Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Reata Pharmaceuticals Secures $32 Million In First Tranche Of Series F Financing
Reata Pharmaceuticals Secures $25 Million In Series E Financing
Reata Pharmaceuticals Secures $22.6 Million In Series D Financing
Reata Pharmaceuticals Secures $12 Million In Series C Financing
Licensing Agreements
Reata Pharmaceuticals Enters Into Licensing Agreement With Kyowa Hakko Kirin
Reata Enters Into An Agreement With Dartmouth College and The University of Texas
Reata Pharmaceuticals Enters Into Licensing Agreement With The University of Texas Southwestern Medical Center And Victoria University of Wellington
Reata Pharmaceuticals Enters Into Licensing Agreement With Dartmouth College And The University of Texas M. D. Anderson Cancer Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
